Literature DB >> 8879103

Cross-reactivity of Shigella flexneri serotype 2a O antigen antibodies following immunization or infection.

L L Van De Verg1, N O Bendiuk, K Kotloff, M M Marsh, J L Ruckert, J L Puryear, D N Taylor, A B Hartman.   

Abstract

To study the cross-reactivity pattern of Shigella flexneri 2a O-antigen antibodies, sera from humans and monkeys challenged with S. flexneri 2a, and from humans and guinea pigs immunized with a recombinant vaccine expressing serotype 2a O-antigen, were tested against a panel of lipopolysaccharide extracted from heterologous S. flexneri. Sera from the two groups of humans, who were volunteers in either a clinical challenge or vaccination study, showed similar patterns: cross-reactivity was more often seen with IgA antibodies, and these were mostly cross-reactive with serotype 2b, which shares the type II antigen, and serotypes 1a, 5a, and Y, which share 4 or 3, 4 group antigen, with 2a. The majority of sera from immunized guinea pigs showed both IgG and IgA cross-reactivity with 1a, 5a, and Y, but not 2b. The majority of sera from challenged monkeys showed cross-reactivity with almost all flexneri serotypes tested, with 1a, 2b, and Y being recognized most often, and the cross-reactive antibodies were more often IgG than IgA. These results show that either immunization or challenge with the 2a serotype induces cross-reactive antibodies which recognize similar subsets of heterologous serotypes, and suggest that it may be possible to design multivalent vaccines against S. flexneri.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8879103     DOI: 10.1016/0264-410x(96)00006-0

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  12 in total

Review 1.  Use of Pathogen-Specific Antibody Biomarkers to Estimate Waterborne Infections in Population-Based Settings.

Authors:  Natalie G Exum; Nora Pisanic; Douglas A Granger; Kellogg J Schwab; Barbara Detrick; Margaret Kosek; Andrey I Egorov; Shannon M Griffin; Christopher D Heaney
Journal:  Curr Environ Health Rep       Date:  2016-09

2.  Characterization of a multicomponent live, attenuated Shigella flexneri vaccine.

Authors:  BreOnna C DeLaine; Tao Wu; Christen L Grassel; Avital Shimanovich; Marcela F Pasetti; Myron M Levine; Eileen M Barry
Journal:  Pathog Dis       Date:  2016-04-21       Impact factor: 3.166

3.  Stable Chromosomal Expression of Shigella flexneri 2a and 3a O-Antigens in the Live Salmonella Oral Vaccine Vector Ty21a.

Authors:  Madushini N Dharmasena; Manuel Osorio; Kazuyo Takeda; Scott Stibitz; Dennis J Kopecko
Journal:  Clin Vaccine Immunol       Date:  2017-12-05

4.  Epidemiology and genetic characterization of Shigella flexneri strains isolated from three paediatric populations in Egypt (2000-2004).

Authors:  S F Ahmed; M S Riddle; T F Wierzba; I Abdel Messih; M R Monteville; J W Sanders; J D Klena
Journal:  Epidemiol Infect       Date:  2006-05-11       Impact factor: 2.451

5.  Monoclonal Antibodies to Shigella Lipopolysaccharide Are Useful for Vaccine Production.

Authors:  Jisheng Lin; Mark A Smith; William H Benjamin; Robert W Kaminski; Heather Wenzel; Moon H Nahm
Journal:  Clin Vaccine Immunol       Date:  2016-08-05

6.  Strategy for cross-protection among Shigella flexneri serotypes.

Authors:  F R Noriega; F M Liao; D R Maneval; S Ren; S B Formal; M M Levine
Journal:  Infect Immun       Date:  1999-02       Impact factor: 3.441

Review 7.  Vaccines for the prevention of diarrhea due to cholera, shigella, ETEC and rotavirus.

Authors:  Jai K Das; Anjali Tripathi; Anum Ali; Amman Hassan; Chesarahima Dojosoeandy; Zulfiqar A Bhutta
Journal:  BMC Public Health       Date:  2013-09-17       Impact factor: 3.295

8.  Shigella isolates from the global enteric multicenter study inform vaccine development.

Authors:  Sofie Livio; Nancy A Strockbine; Sandra Panchalingam; Sharon M Tennant; Eileen M Barry; Mark E Marohn; Martin Antonio; Anowar Hossain; Inacio Mandomando; John B Ochieng; Joseph O Oundo; Shahida Qureshi; Thandavarayan Ramamurthy; Boubou Tamboura; Richard A Adegbola; Mohammed Jahangir Hossain; Debasish Saha; Sunil Sen; Abu Syed Golam Faruque; Pedro L Alonso; Robert F Breiman; Anita K M Zaidi; Dipika Sur; Samba O Sow; Lynette Y Berkeley; Ciara E O'Reilly; Eric D Mintz; Kousick Biswas; Dani Cohen; Tamer H Farag; Dilruba Nasrin; Yukun Wu; William C Blackwelder; Karen L Kotloff; James P Nataro; Myron M Levine
Journal:  Clin Infect Dis       Date:  2014-06-23       Impact factor: 9.079

Review 9.  The Shigella human challenge model.

Authors:  C K Porter; N Thura; R T Ranallo; M S Riddle
Journal:  Epidemiol Infect       Date:  2012-08-21       Impact factor: 4.434

10.  Detecting and Discriminating Shigella sonnei Using an Aptamer-Based Fluorescent Biosensor Platform.

Authors:  Myeong-Sub Song; Simranjeet Singh Sekhon; Woo-Ri Shin; Hyung Cheol Kim; Jiho Min; Ji-Young Ahn; Yang-Hoon Kim
Journal:  Molecules       Date:  2017-05-17       Impact factor: 4.411

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.